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Background: Classical Kaposi’s Sarcoma (cKS) is a rare vascular tumor, which develops in subjects infected with
Human Herpesvirus-8 (HHV-8). Beside the host predisposing factors, viral genetic variants might possibly be related
to disease development. The aim of this study was to identify HHV-8 variants in patients with cKS or in HHV-8
infected subjects either asymptomatic or with cKS-unrelated cutaneous lymphoproliferative disorders.
Methods: The VR1 and VR2 regions of the ORF K1 sequence were analyzed in samples (peripheral blood and/or
lesional tissue) collected between 2000 and 2010 from 27 subjects with HHV-8 infection, established by the
presence of anti-HHV-8 antibodies. On the basis of viral genotyping, a phylogenetic analysis and a time-scaled
evaluation were performed.
Results: Two main clades of HHV-8, corresponding to A and C subtypes, were identified. Moreover, for each subtype, two
main clusters were found distinctively associated to cKS or non-cKS subjects. Selective pressure analysis showed twelve
sites of the K1 coding gene (VR1 and VR2 regions) under positive selective pressure and one site under negative pressure.
Conclusion: Thus, present data suggest that HHV-8 genetic variants may influence the susceptibility to cKS in
individuals with HHV-8 infection.
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Human Herpesvirus-8 (HHV-8) infection is associated with
three human malignancies: Kaposi’s sarcoma (KS), primary
effusion lymphoma (PEL), and multicentric Castleman’s
disease (MCD) [1]. KS is a vascular tumor thought to arise
from HHV-8 infected cells of endothelial origin, whereas
PEL and MCD appear of B-cell origin [2]. However, HHV-
8 may also cause a persistent infection without clinical
symptoms [3] or characterized by an acute inflammatory
syndrome [4,5]. A significant high rate of HHV-8 infected
subjects was also found among patients with cutaneous
lymphoproliferative diseases [6,7], characterized by the
proliferation of T lymphocytes showing different grades of* Correspondence: cordiali-fei@ifo.it
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unless otherwise stated.tropism for the epidermal layer of the skin, as the early
stage Mycosis Fungoides (eMF) [8] or the cutaneous T cell
lymphoma Mycosis Fungoides (MF) [9].
Although HHV-8 infection alone might not represent
the primary cause for KS development [10], the patho-
genic processes leading to KS development correlate with
HHV-8 reactivation from latency, increased viral load and
production of viral factors, which interfere with host cellu-
lar functions and allow the virus to escape from the host
immune response [11]. Additionally, host predisposing
factors appear to play a part in promoting the disease,
including either immune suppression or an unbalanced
immune response [11-13]. In fact, either an association
with HIV [14,15] or EBV co-infections [15-17] and a gen-
etic background involving genes coding for inflammatory
cytokines [18,19] or cell cycle control proteins [20] repre-
sent high risk factors for KS development. On the othertral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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multiple viral genes can regulate pathways controlling the
switch between latent and lytic replication [21] and alter
intracellular signaling pathway important in regulating the
cell cycle as PI3K/AKT/MTOR [22]. In fact, the HHV-8
genome contains 87 open reading frames (ORFs) that en-
code homologues to cellular proteins involved in signal
transduction, cell cycle regulation, and/or inhibition of
apoptosis. All of them play key roles in cell growth and
might be potentially involved in cell transformation [2].
Emerging evidence suggests that the HHV-8 ORF74 gene,
which encodes the viral G protein-coupled receptor
(vGPCR), may play a part in KS development [23,24].
However, other genes might possibly be implicated in cell
transformation [2,25,26], including ORF-K1, encoding a
transmembrane glycoprotein (K1) expressed by infected
cells, with a cytoplasmic tail containing a constitutively
active immunoreceptor tyrosine activation motif (ITAM),
which transduces extracellular signals to elicit cellular
activation [27,28]. Moreover, K1 appears to be involved in
endothelial cell immortalization [29] and its expression in
epithelial and endothelial cells results in the production of
vascular endothelial growth factor (VEGF) and matrix
metalloproteinase MMP-9 [30], which can favor tumor
angiogenesis and tumor cell growth in vivo [31,32].
Sequence analysis of the highly variable ORF K1 regions
has allowed the identification of four main HHV-8 sub-
types (A, B, C, D) [33] presenting a different distribution
in the world: subtype A and C predominate in Europe and
USA, while B subtype predominates in Africa and D is
present in the Pacific islands [34]. In addition, recently
identified subtypes include E, found to be predominant in
ancient populations, like Brazilian Amerindians [35], Z,
detected in Zambian children [36] and F, identified
in Ugandan Bantu tribe [37]. Although viral genetic
variants have been suggested to be related to disease
activity [38,39], it is still unclear whether different
genotypes are associated with diverse clinical settings
or rates of KS progression. The aim of this study was to
investigate HHV-8 variants, through the analysis of
ORF K1 sequences, including the variable regions VR1
and VR2, in patients with cKS or in HHV-8 infected
subjects either without clinical symptoms or presenting
cutaneous proliferative disorders, including MF or
eMF. We further analyzed the nonsynonymous nucleo-
tide mutations in the K1 protein-coding sequence to
identify possible molecular variants associated with KS
development.
Methods
Design of the study
A retrospective study to assess HHV-8 genetic variants in
cKS patients and HHV-8-infected subjects either asymp-
tomatic or with cutaneous proliferative disorders (MF orEsMF) was planned. Lesional tissue specimens or frozen
peripheral blood mononuclear cells (PBMCs), collected,
upon informed consent, between 2000 and 2010 were
employed for ORFK1 gene amplification, nucleotide se-
quencing, phylogenetic analysis and analysis of nonsy-
nonymous mutations. The study was approved by the
Institutional Ethical Committee ( Prot. IFO/CE 1352/02).
Subjects and samples
Table 1 summarizes the clinical and demographic charac-
teristics of the study subjects. The study was performed on
a total of 27 subjects, 21 male and 6 female, aged between
38 and 87 yrs (median age: 68 yrs). All originated from
central (Abruzzo, Lazio) or south (Calabria, Campania)
Italy. Four subjects were clinically asymptomatic, 15
were affected by cKS, 8 presented a cutaneous lympho-
proliferative diseases (4 had diagnosis of eMF and 4
of MF, according the WHO-EORTC classification) [8,9].
Staging of KS was performed according to the localization
and vascularisation of skin lesions [40], as well as the
occurrence of visceral involvement [38]. Clinical diagnosis
were confirmed by histological analysis in all patients.
Tissue and PBMC samples employed to analyze the
HHV-8 ORF K1 sequence were collected between 2000
and 2010, and kept stored at −80°C.
Laboratory procedures
Anti-HHV-8 antibodies
Anti-HHV-8 antibody titres have been assessed in sera by
an immunofluorescence based assay (IFA) using BCBL-1
cells as substrate, as previously described [6]. Briefly, cells
were plated on slides either untreated or after 72 hrs
incubation with 12-O-tetradecanoyl-phorbol-13 acetate
(20 ng/ml, TPA, Sigma, St Louis, MO) to induce the
expression of antigens associated to the lytic cycle.
HHV-8 viral load
Extraction of DNA from biological samples was performed
by a semi-automated procedure (NucliSens Easy MAG,
Biomérieux, France). To establish viral load, DNA was
isolates from the sera and HHV-8 genome detection
and quantitation (genome equivalents gEq/mL), was
performed by a commercial kit (HHV8 Q-PCR Alert,
Nanogen Advanced Diagnostics, Italy), according to the
manufacturer instructions. The procedure involved a real
time amplification reaction for a gene region that codifies
the protein of the HHV-8 capsid gene (ORF26).
ORFK1 sequencing
Viral DNA was extracted from peripheral blood mono-
nuclear cells (PBMC) and from paraffin-embedded sections
of tissue biopsies, performed for histological analysis, by
the described semi-automated procedure (Nuclisens Easy
MAG, Biomerieux SA, FR). The ORFK1 was amplified by
Table 1 Characteristics of the patients and reference subjects (n = 27)
Sample ID Material Diagnosis Origin Year of sampling Age Sex Genotype Plasma viral load gen eq/mL Clinical stage
26 K Biopsy cKS Central Italy 2008 73 M A 107 B IV
30 K Biopsy cKS South Italy 2008 78 M A 33 B IV
33 K Biopsy cKS South Italy 2008 65 M A 563 B IV
36 K Biopsy cKS South Italy 2009 61 F A 100 B IV
40 K Biopsy cKS Central Italy 2010 38 F A Undetectable A II
47 K Biopsy cKS South Italy 2003 68 M A 105 B IV
48 K Biopsy cKS South Italy 2003 77 M A 190 B IV
4 K Biopsy cKS South Italy 2003 72 F A 100 B II
15 K Biopsy cKS South Italy 2004 68 M A 57 B IV
18 K Biopsy cKS Central Italy 2005 66 M C 70 B IV
20 K Biopsy cKS Central Italy 2007 66 M C 100 A II
21 K Biopsy cKS Central Italy 2007 67 M C 231 B I
27 K Biopsy cKS Central Italy 2008 87 M C 5 B IV
34 K Biopsy cKS South Italy 2009 56 M C 20 A I
37 K Biopsy cKS Central Italy 2009 82 M C 400 B III
14 K PBMC Early MF Central Italy 2010 41 M A Undetectable
3 K Biopsy Early MF South Italy 2002 56 M A Undetectable
77 K Biopsy Early MF Central Italy 2007 74 M A Undetectable
78 K Biopsy Early MF Central Italy 2006 66 M A Undetectable
17 K PBMC MF Central Italy 2005 70 M A 124
13 K Biopsy MF South Italy 2010 72 M C 21200
42 K Biopsy MF Central Italy 2010 66 M C 100
5 K Biopsy MF Central Italy 2003 40 M C 125
1 K PBMC Asymptomatic South Italy 2000 79 F A Undetectable
2 K PBMC Asymptomatic South Italy 2000 83 F A Undetectable
43 K PBMC Asymptomatic Central Italy 2000 80 F C Undetectable
44 K PBMC Asymptomatic Central Italy 2000 61 M C Undetectable
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with specific primers [33]: forward outer primer, 5’- GTT
CTG CCA GGC ATA GTC-3’; revers outer primer AAT
AAG TAT CCG ACC TCA T. PCR products were subse-
quently amplified by forward inner primer 5’-GCG GTT
TGC TTT CGA GG-3’and reverse inner primer 5’-AGA
TAC CAC ACA TGG TT-3’ to obtain a 679 bp fragment
including the two hypervariable regions VR1 (aa 54–93)
and VR2 (aa 191–228) [33,39].
The cycling conditions of the nested PCR were set as
follows. First run initial denaturation: 94°C for 120 sec;
amplification: 35 cycles (94°C for 30 sec, 50°C for 60 sec,
72°C for 120 sec); extension: 72°C for 5 min. Second run
initial denaturation: 94°C for 120 sec; amplification: 29 -
cycles (94°C for 30 sec, 50°C for 45 sec, 72°C for 120 sec);
extension: 72°C for 5 min. The annealing temperature was
set at 50°C for both for outer and inner primers.
Each PCR contained a blank (distilled water instead of
DNA templates) and a positive control (HHV-8 DNA iso-lated from BCBL-1). The reaction products were resolved
by electrophoresis on 1.5% agarose gel, stained with GelRed
Nucleic Acid Gel Stain (Biotium, Inc. 3159, Corporate Place,
Hayward, CA) and subsequently purified by PCR clean-up
protocol to remove salts, enzymes, and other PCR residu-
ates (NucleoSpin Extrct II, Macherey-Nagel, Germany).
The purified DNA samples were sent to Eurofins MWG
Operon, Ebersberg, Germay, for sequencing.
Genetic analysis
Datasets
Two datasets were built. The first dataset contained 27
sequences of the ORFK1 gene, including VR1 and VR2
segments, plus 11 specific reference sequences. All refer-
ence sequences were downloaded from the National
Centre for Biotechnology Information (http://www.ncbi.
nlm.nih.gov/). Reference sequences (genotype A: JN8004
86.1, AF151688.1, JN800487.1, AF130284.1, KF781665.1,
GU097427.1; genotype C: FJ866517.1, DQ394064.1, DQ3
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basis of the following criteria: 1) sequences already pub-
lished in peer-reviewed journals; 2) no uncertainty about
the genotype assignment. The second dataset contained
27 sequences of HHV-8 K1 from the study population
and it was used to estimate the mean evolutionary rate
and to perform the time-scaled phylogeny.
Likelihood mapping
The phylogenetic signal of each sequence dataset was in-
vestigated by means of the likelihood mapping analysis of
10,000 random quartets generated using TreePuzzle [41].
Groups of four randomly chosen sequences (quartets)
were evaluated. For each quartet, the three possible
unrooted trees were reconstructed using the maximum
likelihood approach under the selected substitution model.
The likelihood of each topology was estimated with the
maximum likelihood method and the three likelihoods are
reported as a dot in an equilateral triangle (the likelihood
map). Three main areas in the map could be distinguished:
the three corners representing fully resolved tree topologies,
i.e. the presence of treelike phylogenetic signal in the data;
the center, which represents stalike phylogeny, and the
three areas on the sides indicating nework-like phylogeny,
i.e. presence of recombination or conflicting phylogen-
etic signals. Extensive simulation studies have shown
that > 33% dots falling within the central area indicate
substantial star-like signal, i.e. a star-like outburst of
multiple phylogenetic lineages [41].
Phylogenetic analysis
The sequences of all datasets were aligned using Clustal
X as already described [42] and manually edited by
Bioedit [43]. Subtype of HHV8 sequences was determined
uploading sequences individually into the Bioafrica Oxford
HHV8 Automated Subtyping Tool [44] (http://bioafrica.
mrc.ac.za/rega-genotype/html/indexhhv8.html) and con-
firmed by phylogenetic analysis. The maximum likelihood
(ML) phylogenetic tree was generated with the HKY+ I +G
model of nucleotide substitution, by using Phyml v 3.0.
The evolutionary model was chosen as the best-fitting nu-
cleotide substitution model in accordance with the results
of the hierarchical likelihood ratio test (HLRT) imple-
mented in Modeltest software version 3.7 [45]. The
statistical robustness and reliability of the branching
order within the phylogenetic trees was confirmed by
the bootstrap analysis and considering as significant
statistical support a bootstrap value > 70%.
Bayesian phylogenetic analysis: evolutionary rate estimate
and dated tree
Bayesian Phylogenetic analysis was conducted by means
of MrBayes using HKY as a model of nucleotide substi-
tution. A Markov Chain Monte Carlo (MCMC) searchwas made for 10 × 106 generations using tree sampling
every 100th generation and burn-in fraction of 25%
[46,47].
The dated tree and the evolutionary rate of the second
dataset were co-estimated by using a Bayesian MCMC
approach (Beast v. 1.7.4) implementing a HKY + Invari-
ant + Gamma model using both a strict and an uncorre-
lated log-normal relaxed clock model [48,49].
As coalescent priors, were compared four parametric
demographic models of population growth (constant size,
exponential, logistic growth, expansion) and a Bayesian
skyline plot (BSP, a non-parametric piecewise-constant
model). The best fitting models were selected by means of
a Bayes factor (BF, using marginal likelihoods) imple-
mented in Beast.
In accordance with Kass and Raftery [50] the strength
of the evidence against H0 was evaluated as follows:
2lnBF < 2 = no evidence; 2–6 =weak evidence; 6–10 =
strong evidence; and >10 = very strong evidence. A negative
2lnBF indicates evidence in favour of H0. Only values of ≥ 6
were considered significant.
The MCMC chains were run for at least 100 million
generations, and sampled every 10,000 steps. Conver-
gence was assessed on the basis of the effective sampling
size (ESS). Only ESS values of > 250 were accepted.
Uncertainty in the estimates was indicated by 95% highest
posterior density (95% HPD) intervals. Statistical support
for specific clades was obtained by calculating the poster-
ior probability of each monophyletic clade.
Selective pressure analysis
Comparison of relative fixation rates of synonymous (silent)
and nonsynonymous (amino acid-altering) mutations
provides a means for understanding the mechanisms of
molecular sequence evolution. The nonsynonymous/
synonymous rate ratio (ω = dN/dS) is an important
indicator of selective pressure at the protein level, with
ω = 1 meaning neutral mutations, ω < 1 purifying selec-
tion, and ω > 1 diversifying positive selection [51,52].
The CODEML program implemented in the PAML
3.14 software package (http://abacus.gene.ucl.ac.uk/soft-
ware/paml.html) [51] was used to investigate the adaptive
evolution of the K1 of HHV-8 Virus.
Six models of codon substitution: M0 (one-ratio), M1a
(nearly neutral), M2a (positive selection), M3 (discrete),
M7 (beta), and M8 (beta and omega) were used in this
analysis [52]. Since these models are nested, we used
codon-substitution models to fit the model to the data
using the likelihood ratio test (LRT) [53]. The discrete
model (M3), with three dN/dS (ω) classes, allows ω to
vary among sites by defining a set number of discrete
site categories, each with its own ω value. Through
maximum-likelihood optimization, it is possible to estimate
the ω and P values and the fraction of sites in the aligned
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algorithm calculates the a posteriori probability of each
codon belonging to a particular site category. Using the
M3 model, sites with a posterior probability exceeding
90% and a ω value > 1.0 were designated as being “positive
selection sites” [54]. The site rate variation was evaluated
comparing M0 with M3, while positive selection was
evaluated comparing M1 with M2. The Bayes empirical
Bayes (BEB) approach implemented in M2a and M8
was used instead to determine the positively selected
sites by calculating the posterior probabilities (P) of ω
classes for each site [54]. It is worth noting that PAML
LRTs have been reported to be conservative for short
sequences (e.g. positive selection could be underesti-
mated), although the Bayesian prediction of sites under
positive selection is largely unaffected by sequence length
[55,56]. The dN/dS rate (ω) was also estimated by the ML
approach implemented in the program HyPhy [57]. In
particular, the global (assuming a single selective pressure
for all branches) and the local (allowing the selective
pressure to change along every branch) models were com-
pared by likelihood ratio test (LRT). Site-specific positive
and negative selection were estimated by two different
algorithms: the fixed-effects likelihood (FEL), which fits an
ω rate to every site and uses the likelihood ratio to test if
dN = dS; and random effect likelihood (REL), a variant of
the Nielsen–Yang approach [55] which assumes that a
discrete distribution of rates exists across sites and allows
both dS and dN to vary independently site by- site. The
three methods have been described in more detailA
Figure 1 Likelihood mapping analysis of K1 gene (VR1 and VR2 regio
three possible unrooted trees for a set of four sequences (quartets) selecte
represent, respectively, tree-like, or network-like phylogenetic signal in the
(phylogenetic noise). Panel A and B represent the first and second data seelsewhere [58]. In order to select sites under selective
pressure and keep our test conservative, a P value of ≤ 0.1
or a posterior probability of ≥ 0.9 as relaxed critical values
was assumed.
For evolutionary analysis, the reference sequence Ac-
cession Number DQ394068 was used to trace the exact
position of the amino acids found under selection.Statistical analysis
To test the differences between the two main clades and
clusters in the phylogenetic tree respect to KS develop-
ment, and the association of amino-acid sequences with
clinical settings, the Fisher’s exact test for the categorical
variables was used. P values <0.05 were considered sta-
tistically significant. Calculations of all statistical tests
were performed by using SPSS V.21 Software.Results
Virological parameters
All subjects had antibodies against either latent or lytic
phase HHV-8 antigens with the following median titers and
ranges. Asymptomatics: 1:80 (1:20–1:640); KS patients:
1:640 (160–5120); eMF and MF: 1:80 (1:20 – 1:160).
Thirteen out of 15 KS patients and all the 4 MF patients
had detectable HHV-8 DNA (Table 1). In Table 1 are also
shown data of viral genotyping, as assessed by the se-
quence analysis of the ORFK1 region. As expected, only
type A or C viruses were found in the study population.B
ns) sequences of HHV-8. Each dot represents the likelihoods of the
d randomly from the data set: dots close to the corners or the sides
data. The central area of the likelihood map, represents star-like signal
t, respectively.
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The phylogenetic noise of each dataset was investigated
by means of likelihood mapping (Figure 1A, B). The per-
centage of dots falling in the central area of the triangles
was 2.6% for the first dataset, 1.9% for the second data-
set; as none of the dataset showed more than 33% of
noise, all of them were considered to contain sufficient
phylogenetic signal.
Phylogenetic analysis
Maximum Likelihood phylogenetic tree of the first dataset
showed 11 of 27 (41%) sequences classified as subtype C
and 16 of 27 (59%) as subtype A (Figure 2) and distributed
in two main clades (clade I and II respectively). Within
the clade I two different statistically supported clusters
were apparent (cluster IA and IB respectively). Cluster IA
included 5 closely related isolates from KS patients and
one isolate from MF patient, and cluster IB includedFigure 2 ML phylogenetic tree for the first subtyping data set. The tre
with the best fitting nucleotide substitution model according to a hierarch
bottom indicating 0.04 nucleotide substitutions per site. Sequences corresp
black (KS), red (MF), orange (eMF), green (no clinical symptoms). The asteris
for the clade subtending that branch (bootstrap value > 70%).isolates from 2 MF patients and 2 asymptomatic HHV-8
infected subjects and one isolate from KS patient. The
same distribution occurred within the clade II where two
main statistically supported clusters (cluster IIA and IIB
respectively) were apparent. Cluster IIA, included isolates
from 4 Early MF and 1 MF patients, 2 asymptomatic
HHV-8 infected subjects and 1 KS patient; and cluster IIB
included closely related isolates from KS patients.
The phylogenetic relationships among the different
sequences of HHV-8 were supported by the bootstrap
analysis with values >70%.
Bayesian phylogenetic analysis: evolutionary rate
estimate and dated tree
The posterior probability >97% as statistical support for
specific clades and cluster obtained in ML confirmed all
the clades and clusters found (Data not shown). The
Bayesian phylogenetic tree was built using the 27 isolatese was rooted by the midpoint rooting. Branch lengths were estimated
ical likelihood ratio test, and were drawn to scale with the bar at the
onding to HHV-8 isolates from different diseases are evidentiated in
k (*) along the branches represents significant statistical significance
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HHV8 evolutionary rate was 6.42 × 10−4 substitution/
site/year (95% HPD: 3.5706 × 10−6 - 1.4394 × 10−3).
The BF analysis showed that the relaxed clock fitted
the data significantly better than the strict clock (2lnBF
between the strict and relaxed clock was in favour of the
second). Under the relaxed clock the BF analysis showed
that the exponential growth model was better than the
other models (2lnBF > 127). On the basis of this evolution-
ary rate, we estimated the time of the most common recent
ancestor (tMRCAs) of the entire tree: in particular, the root
of the tree had a tMRCA of 227 years before 2010 and
dated back to the year 1783 (95% HPD: 1391–1988).
Four statistically supported clades (1, 2, 3 and 4) and a
group of two sequences were evidenced. Clade 1 was
dated back to the year 1889 (95% HPD: 1683–1995). One
sequence labelled as 30 K was as out-group of the clade.
Inside clade 1 two clusters (1a and 1b) were identified.
Cluster 1a included one sequence labelled 2 K, isolated
from an asymptomatic subject and three sequences iso-
lated from eMF patients, which dated back to the yearFigure 3 Bayesian time-scaled tree of the 27 K1 HHV-8 gene sequenc
estimated date of the origin and the uncertainty indicated by 95% highest po
from different diseases are evidentiated in black (KS), red (MF), orange (eMF),
significant statistical significance for the clade subtending that branch (poster1976 (95% HPD: 1927–2000). Cluster 1b dated back to
the year 1965 (95% HPD: 1895–1999), included only three
sequences, one isolated from an asymptomatic subject,
labelled 2 K; one sequence isolated from a eMF patient,
labelled 14KLP@10; and one sequence from a MF patient,
labelled 17 K.
Clade 2, that was dated back to the year 1905 (95% HPD:
1721–1998) included only one statistically supported
cluster (2a) where only closely related Kaposi sequences,
isolated from tissue, appeared. These sequences dated
back to the year 1950 (95% HPD: 1845–2002).
Clade 3, that was dated back to the year 1911 (95%
HPD: 1744–2001) contained one statistically supported
cluster (3a) including only two sequences isolated from
KS and dated back to the year 1964 (95% HPD: 1891–
2004).
Clade 4, that was dated back to the year 1918 (95%
HPD: 1750–1999) contained one Kaposi sequence iso-
lated from tissue labelled 34 K, sequences isolated from
two asymptomatic subjects and one sequence isolated
from MF patient, labelled 42 K.es. The numbers at the root and at the internal nodes represent the
sterior density (95% HPD) intervals. Sequences corresponding to isolates
green (no clinical symptoms) The asterisks (*) along a branch represent
ior probability >97%). The line at the bottom represents time (in years).
Table 2 Selection analysis for the K1 gene of HHV-8 showing the effect of molecular sequence variation on amino-acid
substitution
Negatively selected sites* 102(Gln)
(ω <1)**
HYPHY software
Positively selected sites* 44 (Glu,Ala,Thr,His,Ser,Pro) 58 (Ser,Phe,Trp,Leu,Val) 60 (Leu,Pro,Met,Ala)
(ω >1) ** 62 (Gln, Asp, Lys,Glu,Thr,Arg) 66 (Leu,Phe,Thr,Asn,Ser,His) 66 (Leu,Phe,Thr,Asn,Ser,His)
HYPHY and PAML software 67 (Val,Pro,Ala,Gly,Ile) 68 (Gly,Val,Ala,Ser,Leu,Phe,Asp) 69 (Thr,Asp,Arg,Asn,Ile)
70 (Ile,Phe,Leu) 71 (Ile,Ser,Val,Asn,Ala,Thr,His) 75 (Val,Thr,Ser,Leu)
101 (Gly,Ala,Val,Arg)
*Negatively selected sites and Positively selected sites are numbered according to amino acid position of K1 of HHV-8 Virus isolate accession number DQ394068.
**ω = dN/dS ratio of divergence at non-synonymous (nucleotide sites at which substitution causes an amino-acid change) and synonymous sites (nucleotide sites
at which substitution does not causes an amino-acid change).
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back to the year 1934 (95% HPD: 1803–2002) contained
only sequences isolated from KS patients.Evolutionary analysis
Selection pressure analysis on the K1 of HHV8 Virus
revealed twelve statistically supported positively selected
sites according to the reference sequence Accession
Number DQ394068 (both by using HYPHY, PAML soft-
ware) (Table 2). The α parameter of the γ distribution
was < 1, shoving as this distribution has a characteristic
L-shape, suggesting a nucleotide substitution rate het-
erogeneity across sites.
The average ω ratio ranges from 0.4214 to 3.099
among all models (Table 3), although in average the K1
of HHV8 virus, is under strong positive selection (ω > 1).
The discrete model (M3) fits the data significantly
better than one ratio model (M0) with LRT statistic (2
Δl = 285.02). The beta model (M7) is rejected when
compared with the beta & ω model (M8) with LRT
statistic (2 Δl = 193.36). The discrete model (M3) indi-
cates about 1% of sites are under positive selection
with ω2 = 16.6545 (p < 0.05 d.f. = 4). Similarly in the
beta & ω model (M8) there was 1.1% of sites are under
positive selection with ω = 13.3798 (p < 0.05 d.f. = 2).
Only one negatively selected site, identified by FEL, for
the K1 gene of HHV8 virus was showed in Table 2.Table 3 Likelihood Values and Parameter Estimates for the Se
Model Free parameters Log likelihood Parame
M0, one ratio 1 −2327.23 ω = 2.11
M1, neutral 1 −2336.44 p0 = 0.1
M2, selection 3 −2186.37 p0 = 0.2
M3, discrete 5 −2184.71 p0 = 0.6
M7, beta 2 −2283.13 P = 0.00
M8, beta, and ω 4 −2186.45 p0 = 0.8Statistical analysis of disease association
The genotype A or C distribution, analyzed by contingency
tables, was not significantly associated with geographic ori-
gin (Central vs South Italy) or with diagnosis of KS. The
analysis of the association of clusters of ORFK1 with
KS development by Fisher exact test showed a signifi-
cant of cluster IIb (6 KS, 0 no KS), vs IIa (one KS, 7 no
KS), p = 0.05; while the association of cluster Ia (5 KS, 1
no KS) vs Ib (1 KS, 4 no KS), did not reach a significant
value, p = 0.08 (Table 4). The amino-acid substitutions
at the 12 hypervariable codon sites for each sequence
are described in Table 5. One similar sequence could be
identified in 4/12 HHV-8 positive subjects without KS
(3 K, 77 K, 78 K, 2 K) while it was not found in any KS
sample (p = 0.03)Discussion
KS is characterized by angioproliferative multifocal tumors
of the skin or mucosa and less frequently the viscera,
largely comprised of cells of endothelial origin with a
unique spindled morphology, accompanied by a variable
chronic inflammatory infiltrate [1]. Four different forms of
KS are recognized: Classic (sporadic), African (endemic),
acquired immune deficiency syndrome (AIDS)-associated
(epidemic), and Transplant or immunosuppression-
associated (iatrogenic) KS, all associated to prior in-
fection with HHV-8 [1,2]. However, HHV-8 infectionlection Analysis of the K1 of HHV-8
ters estimates Avg ω
1 2.111
49; p1 = 0.851 1.000
90; p1 = 0.553; p2 = 0.156; ω2 = 12.812 2.556
48; p1 = 0.218; p2 = 0.134; ω0 = 0.340; ω1 = 2.954; ω2 = 16.654 3.099
5, q = 0.006 0.421
43; P = 0.012; q = 0.005; p1 = 0.156; ω = 13.380 2.683
Table 4 Contingency table analysis to assess the
association between HHV-8 clusters and KS development
Clades Clusters KS All Fisher
exact testNo Yes
I IA 1 (16.7%) 5 (83.3%) 6 (100%) P = 0.08
IB 4 (100%) 1 (0.0%) 4 (100%)
II IIA 7 (87.5%) 1 (12.5%) 8 (100%) P = 0.05
IIB 0 (0%) 6 (100%) 6 (100%)
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ment of KS. In fact, progression to KS is believed to
depend on a complex and as yet incompletely understood
interplay between HHV-8 and the host immune system
that allows for the establishment of a tumor-promoting


















15 K A cKS Ala Phe Pro Asp Ph
18 K C cKS Thr Phe Leu Gln Th
20 K C cKS Thr Phe Leu Gln Th
21 K C cKS Thr Phe Leu Gln Th
26 K A cKS Ala Leu Leu Glu Se
27 K C cKS Thr Phe Leu Glu Th
30 K A cKS His Trp Leu Lys A
33 K A cKS Ala Phe Leu Glu Ph
34 K C cKS Glu Ser Leu Gln Le
36 K A cKS Ala Leu Leu Lys Th
37 K C cKS Thr Phe Met Gln Th
40 K A cKS Ala Val Leu Glu Ph
47 K A cKS Ala Phe Ala Glu Ph
48 K A cKS Ala Trp Leu Arg Th
4 K A cKS Thr Leu Leu Thr H
14 K A eMF Thr Trp Leu Lys Th
3 K A eMF Ser Trp Leu Lys Th
77 K A eMF Ser Trp Leu Lys Th
78 K A eMF Ser Trp Leu Lys Th
13 K C MF Ser Phe Leu Arg Th
17 K A MF Pro Trp Leu Lys Th
42 K C MF Thr Leu Leu Lys Th
5 K C MF Thr Leu Leu Lys Th
1 K A Asympt. Thr Trp Leu Lys Th
2 K A Asympt. Ser Trp Leu Lys Th
43 K C Asympt. Thr Leu Leu Met Th
44 K C Asympt. Thr Leu Leu Lys Th
Contingency tables and Chi square test suggest an association of amino-acid subst
0/15 KS, p = 0.03 (Fisher).life-long infection in the host that depends upon virus-
encoded immune evasion genes and genes that influence
cellular proliferation, survival, migration, angiogenesis and
cytokine/chemokine production [2]. Different cells repre-
sent viral reservoirs in the infected host, including PBMC,
endothelial cells, epithelial cells, and the KS spindle cells
[1]. The host responds to persistent viral infection with a
chronic inflammatory response, thereby facilitating events
that, particularly in the context of immune suppression,
might favor the viral oncogenic potentials. Understanding
the dynamic relationship between host and viral factors
that drives KS oncogenesis is central to the design of
effective strategies to prevent tumor development. To
better understand the HHV-8 contribution to KS devel-
opment, we analyzed the sequences of the ORFK1 region
























e Pro Val Thr Ile Ser Thr Ala
r Val Val Asp Phe Val Ser Val
r Val Ala Arg Leu Val Ser Arg
r Val Val Asn Leu Ile Ser Gly
r Pro Val Thr Ile Ala Thr Ala
r Val Val Asn Leu Ile Ser Gly
sn Ala Ser Thr Ile Asn Leu Ala
e Pro Leu Thr Ile Ala Thr Ala
u Val Gly Thr Ile Ile Val Gly
r Ala Val Thr Ile Thr Thr Ala
r Val Phe Asn Leu Ile Ser Gly
e Pro Val Thr Ile Ala Thr Ala
e Pro Val Thr Ile Ala Thr Ala
r Val Ala Thr Ile Thr Thr Ala
is Gly Val Asn Leu Thr Thr Ala
r Ile Asp Ile Ile His Leu Ala
r Ile Asp Ile Ile Thr Thr Ala
r Ile Asp Ile Ile Thr Thr Ala
r Ile Asp Ile Ile Thr Thr Ala
r Val Val Asn Ile Ser Leu Gly
r Ile Asp Ile Ile Asn Leu Ala
r Val Val Thr Ile Ile Ser Ala
r Val Val Thr Leu Ile Ser Gly
r Ile Asp Ile Ile Asn Leu Ala
r Ile Asp Ile Ile Thr Thr Ala
r Val Asp Thr Leu Ile Ser Gly
r Ile Val Thr Leu Ile Ser Gly
itutions with HHV-8 infection and noKS: 4 sequences (boldface text)/12 vs
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patients or patients with a diagnosis of MF and eMF,
according to the criteria by the International Society for
Cutaneous Lymphomas [8], or clinically asymptomatic
individuals. Although, the pathogenetic role of HHV-8 in
MF and eMF remains to be established, we have previ-
ously found a significantly higher prevalence of HHV-8
infection in patients with the diagnosis of large plaque
parapsoriasis (100%), a benign dermatosis with character-
istics partially overlapping eMF, and in patients with MF
(25%) as compared to that found in the general population
(13,5%). In the same study we could amplify the ORF 26
coding for capsid viral protein even in those subjects with
low anti-HHV-8 antibody titers, and detect ORF73 coded
protein in tissue endothelial cell and some infiltrating
lymphocytes, by immunohistochemistry. Nevertheless
the role of virus in the development of the lesions is
not ascertained [6].
The results of the present study show a statistically
significant clustering of distinct viral isolates in two
major clades corresponding to genotypes A and C. We
did not observe any disease-specific segregation of A or
C. Also the geographical area of origin was not associ-
ated to A or C viral subtypes. In fact, all subjects come
from very close regions of central or south of Italy, with
very similar rates of HHV-8 infection and KS incidence
[3,59,60].
Within each of the major clades, however, HHV-8
isolates were clustered into two further distinguished
subclades, one with significantly distinct distribution,
according to the presence or the absence of KS, the
other showing a distinct distribution, not reaching stat-
istical significance (P = 0.08). This could suggest that
KS patients are infected by HHV-8 strains differing in
the ORFK1 region as compared to non-KS patients.
This finding is further sustained by the bayesian evolu-
tionary analysis showing a cluster (1a) of non-KS asso-
ciated HHV8 strains.
These findings support the notion that viral genetic
variations, as those associated to the ORF-K1 gene, may
be associated to KS and might even play a part in KS
development. In fact, K1 is a multifunctional protein
that can constitutively activate multiple growth signaling
pathways in infected cells [61]. The NH2-terminal region
of K1 specifically interacts with the μ chains of BCR
complexes, and this interaction retains BCR complexes
in the endoplasmic reticulum, preventing their intracel-
lular transport to the cell surface [62]. K1 was shown to
functionally substitute for saimiri transforming protein
(STP) of herpesvirus saimiri (HVS) and induce lymphoma
in common marmosets [63]. Further, K1 induces B-cell
lymphomas in transgenic mice through constitutive Lyn
kinase activation, crucial for the production of VEGF and
NF-kB activation [64,65], and induces MMP-9 and VEGFsecretion from epithelial and endothelial cell lines [30,31].
The VEGF pathway appears implicated in both KS and
MF pathogenesis [31,66].
Conclusion
The main aim of this study was to analyze the variability
rate of HHV-8, including samples from patients with cKS
and from HHV-8 infected subjects without established
HHV-8 associated diseases. The analysis of nucleotide
variation of K1 and the consequent effect on amino-acid
substitutions revealed 12 positively selected sites. One
identical amino-acid sequence at the 12 codon sites under
positive selection pressure could be identified in 4/12
HHV-8 positive subjects without KS, thus suggesting a
role of HHV-8 in the development of the KS in the
infected subjects. Although, the small number of cases
and the long period of enrollment may have introduced
significant bias on the conclusions of this study, our data
encourage the planning of a larger study to to explore
whether K1 polymorphisms may identify HHV-8 variants
influencing the susceptibility to cKS in individuals with
HHV-8 infection.
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